Back to results
US 2003/0170302 A1Published application
Extended release pharmaceutical tablet of metformin
AssigneeBiovail Laboratories, Inc.
InventorsPawan Seth, Benoit Schmidtt
Life of this patent
Estimating the term…
Abstract
The invention provides an extended release pharmaceutical tablet containing: (i) a core comprising by weight, based on the core weight, about 70% to about 99% metformin and pharmaceutically acceptable excipients; and (ii) a coating permeable to metformin. The extended release tablet of the invention exhibit a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released; after about 4 hours, from about 15% to about 90% of the metformin is released; after about 8 hours, from about 50% to about 100% of the metformin is released; after about 12 hours, more than about 75% of the metformin is released.
Claims81
An extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, about 70% to about 99% metformin and pharmaceutically acceptable excipients;
- and
- (ii) a coating permeable to metformin,
- said extended release tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours, from about 15% to about 90% of the metformin is released;
- after about 8 hours, from about 50% to about 100% of the metformin is released;
- after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, about 70% to about 99% metformin and conventional excipients;
- and
- (ii) a coating permeable to metformin consisting essentially by weight, based on the coating weight, of about 20% to about 85% of a water-insoluble, water-permeable film-forming polymer, of about 10% to about 75% of a water soluble polymer and about 3% to about 40% of a plasticizer,
- said extended release tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours, from about 15% to about 90% of the metformin is released;
- after about 8 hours, from about 50% to about 100% of the metformin is released;
- after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, about 70% to about 99% metformin and pharmaceutically acceptable excipients;
- and
- (ii) a coating permeable to metformin consisting essentially by weight, base on the coating weight, from about 50% to about 85% of a water-insoluble, water-permeable film-forming polymer, from about 10% to about 35% of a water soluble polymer and from about 3% to about 15% of a plasticizer,
- said composition exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours, from about 15% to about 90% of the metformin is released;
- after about 8 hours, from about 50% to about 100% of the metformin is released;
- after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release tablet comprising:
- (i) a core comprising by weight, based on the core weight, 70 to 99% of metformin, an expanding agent and pharmaceutically acceptable excipients;
- and
- (ii) a coating permeable to metformin consisting essentially by weight, based on the coating weight, from about 20% to about 50% of a water-insoluble, water-permeable film-forming polymer, from about 35% to about 75% of a water-soluble polymer and from about 15% to about 40% of a plasticizer;
- said tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours from about 15% to about 90% of the metformin is released;
- after about 8 hours from about 50% to about 100% of the metformin is released;
- and after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, 70 to 99% of metformin, a non-hydro colloid expanding agent and pharmaceutically acceptable excipients;
- and
- (ii) a coating permeable to metformin and free of monomeric pore forming agent consisting essentially by weight, based on the coating weight, from about 20% to about 50% of a water-insoluble, water-permeable film-forming polymer, from about 35% to about 75% of a water-soluble polymer and from about 15% to about 40% of a plasticizer;
- said tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours from about 15% to about 90% of the metformin is released;
- after about 8 hours from about 50% to about 100% of the metformin is released;
- and after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, 70 to 99% of metformin, crospovidone, glyceryl behenate, polyvinyl alcohol, silicon dioxide;
- and
- (ii) a coating permeable to metformin and free of monomeric pore forming agent consisting essentially by weight, based on the coating weight, from about 20% to about 50% of a water-insoluble, water-permeable film-forming polymer, from about 35% to about 75% of a water-soluble polymer and from about 15% to about 40% of a plasticizer;
- said tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours from about 15% to about 90% of the metformin is released;
- after about 8 hours from about 50% to about 100% of the metformin is released;
- and after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, 70 to 99% of metformin, crospovidone, glyceryl behenate, polyvinyl alcohol, silicon dioxide;
- and
- (ii) a coating permeable to metformin and free of monomeric pore forming agent consisting essentially by weight, based on the coating weight, from about 20% to about 50% of ethylcellulose, from about 35% to about 75% of polyvinylpyrrolidone and from about 15% to about 40% of stearic acid;
- said tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours from about 15% to about 90% of the metformin is released;
- after about 8 hours from about 50% to about 100% of the metformin is released;
- and after about 12 hours, more than about 75% of the metformin is released.
4 more elements
An extended release pharmaceutical tablet comprising:
- (i) a core comprising by weight, based on the core weight, 70 to 99% of metformin, crospovidone, glyceryl behenate, polyvinyl alcohol, silicon dioxide;
- and
- (ii) a coating permeable to metformin and free of monomeric pore forming agent consisting essentially by weight, based on the coating weight, from about 20% to about 50% of ethylcellulose, from about 35% to about 75% of polyvinylpyrrolidone and from about 15% to about 40% of dibutyl sebacate;
- said tablet exhibiting a dissolution profile such that after about 2 hours, from about 7% to about 60% of the metformin is released;
- after about 4 hours from about 15% to about 90% of the metformin is released;
- after about 8 hours from about 50% to about 100% of the metformin is released;
- and after about 12 hours, more than about 75% of the metformin is released.
4 more elements
Dependencies are inferred from the claim text.